Lv1
4 积分 2022-08-22 加入
Molecular and therapeutic landscape of non-clear cell renal carcinoma
5小时前
待确认
Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial
1个月前
已完结
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
1个月前
已完结
Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study
1个月前
已完结
Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial
1个月前
已完结
Clinical and translational attributes of immune-related adverse events
1个月前
已完结
MANIFEST: Multiomic Platform for Cancer Immunotherapy
2个月前
已完结
Efficacy and biomarker analysis of neoadjuvant disitamab vedotin (RC48‐ADC) combined immunotherapy in patients with muscle‐invasive bladder cancer: A multi‐center real‐world study
2个月前
已完结
Bladder Preservation Strategies in Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group
2个月前
已完结
皖公网安备34019202002308
